VLX600 Disrupts Homologous Recombination and Synergizes with PARP Inhibitors and Cisplatin by Inhibiting Histone Lysine Demethylases

Tumors with defective homologous recombination (HR) DNA repair are more sensitive to chemotherapies that induce lesions repaired by HR as well as PARP inhibitors (PARPis). However, these therapies have limited activity in HR-proficient cells. Accordingly, agents that disrupt HR may be a means to aug...

Descripción completa

Detalles Bibliográficos
Autores principales: Ekstrom, Thomas L., Pathoulas, Nicholas M., Huehls, Amelia M., Kanakkanthara, Arun, Karnitz, Larry M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Small Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419117/
https://www.ncbi.nlm.nih.gov/pubmed/34224364
http://dx.doi.org/10.1158/1535-7163.MCT-20-1099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419117/
https://www.ncbi.nlm.nih.gov/pubmed/34224364
http://dx.doi.org/10.1158/1535-7163.MCT-20-1099

Ejemplares similares